CD274 and neoplasm: Our findings identify TPC2 as a dual-action therapeutic target: its inhibition not only disrupts Ras/Raf/MAPK-driven tumour proliferation but also enhances tumour immunogenicity by increasing MHC-I and reducing PD-L1 expression.